Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy

被引:38
|
作者
Sainz-Esteban, Aurora [3 ]
Prasad, Vikas [1 ,2 ]
Schuchardt, Christiane [1 ,2 ]
Zachert, Carolin [1 ,2 ]
Manuel Carril, Jose [3 ]
Baum, Richard P. [1 ,2 ]
机构
[1] Zent Klin Bad Berka, Dept Nucl Med, D-99437 Bad Berka, Germany
[2] Zent Klin Bad Berka, Ctr PET CT, D-99437 Bad Berka, Germany
[3] Hosp Univ Marques de Valdecilla, Dept Nucl Med, Santander, Spain
关键词
Lu-177-DOTA-TATE; Dosimetry scan; Ga-68-DOTA-TATE; Neuroendocrine tumour; RADIOLABELED SOMATOSTATIN ANALOG; TYR(3) OCTREOTATE; BIODISTRIBUTION; SCINTIGRAPHY; AFFINITY; GA-68;
D O I
10.1007/s00259-011-2003-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose The aim of the study was to compare sequential Lu-177-DOTA-TATE planar scans (Lu-177-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic Ga-68-DOTA-TATE positron emission tomography (PET)/CT (Ga-68-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods. Methods A total of 44 patients (59 +/- 11 years old) with biopsy-proven NET underwent Ga-68-DOTA-TATE and Lu-177-DOTA-TATE imaging within 7.9 +/- 7.5 days between the two examinations. Lu-177-DOTA-TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on Lu-177-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on Ga-68-DOTA-TATE studies obtained before PRRT. Results A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were Ga-68-DOTA-TATE positive and Lu-177-DOTA-TATE negative, whereas 9 were Ga-68-DOTA-TATE negative and Lu-177-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for Lu-177-DOTA-TATE as compared to Ga-68-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h) Lu-177-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (n=77; mean size 3.8 cm) were significantly larger than discordant lesions (n=38; mean size 1.6 cm) (p<0.05). No such significance was found for differences in maximum standardized uptake value (SUVmax). However, concordant liver lesions with a score from 1 to 3 in the 72-h (177)LuDOTA- TATE scan had a lower SUVmax (n=23; mean 10.9) than those metastases with a score of 4 (n=97; mean SUVmax 18) (p<0.05). Conclusion Although Lu-177-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for thedetection of metastases, they failed to pick up 9% of lesions seen on the Ga-68-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.
引用
收藏
页码:501 / 511
页数:11
相关论文
共 50 条
  • [41] 68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma
    Derlin, Thorsten
    Sohns, Jan M.
    Hueper, Katja
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (04) : E210 - E211
  • [42] A Comparison of 68Ga-DOTA-TATE and 18F-FDG PET/CT Imaging on Patients with Pancreatic Neuroendocrine Neoplasm (pNEN)
    Zhang, P.
    Yu, J.
    Lu, M.
    Shen, L.
    Yang, Z.
    Li, J.
    NEUROENDOCRINOLOGY, 2017, 105 : 178 - 178
  • [43] Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review
    D. Magalhães
    I. L. Sampaio
    G. Ferreira
    P. Bogalho
    D. Martins-Branco
    R. Santos
    H. Duarte
    Journal of Endocrinological Investigation, 2019, 42 : 249 - 260
  • [44] Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review
    Magalhaes, D.
    Sampaio, I. L.
    Ferreira, G.
    Bogalho, P.
    Martins-Branco, D.
    Santos, R.
    Duarte, H.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (03) : 249 - 260
  • [45] Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours
    Alexander Haug
    Christoph J. Auernhammer
    Björn Wängler
    Reinhold Tiling
    Gerwin Schmidt
    Burkhard Göke
    Peter Bartenstein
    Gabriele Pöpperl
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36 : 765 - 770
  • [46] Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours
    Haug, Alexander
    Auernhammer, Christoph J.
    Waengler, Bjoern
    Tiling, Reinhold
    Schmidt, Gerwin
    Goeke, Burkhard
    Bartenstein, Peter
    Poepperl, Gabriele
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (05) : 765 - 770
  • [47] Dosimetry in peptide receptor radionuclide therapy (PRRNT): comparative results using Lu-177 DOTA-TATE, DOTA-NOC und DOTA-TOC
    Schuchardt, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S244 - S244
  • [48] Effectivity of a combined treatment with the m-TOR inhibitor RAD001 and Peptide Receptor Radionuclide therapy with Lu-177 DOTA TATE evaluated with Ga-68 DOTA TATE PET in a tumor model of the mouse
    Zellmer, J.
    Vomacka, L.
    Boening, G.
    Gildehaus, F. J.
    Carlsen, J.
    Mille, E.
    Hacker, M.
    Bartenstein, P.
    Haug, A. R.
    Ilhan, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S229 - S229
  • [49] Repeated cycles of peptide receptor radionuclide therapy (PRRT) - Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET
    Pach, Dorota
    Sowa-Staszczak, Anna
    Kunikowska, Jolanta
    Krolicki, Leszek
    Trofimiuk, Malgorzata
    Stefanska, Agnieszka
    Tomaszuk, Monika
    Glowa, Boguslaw
    Mikolajczak, Renata
    Pawlak, Dariusz
    Jabrocka-Hybel, Agata
    Hubalewska-Dydejczyk, Alicja B.
    RADIOTHERAPY AND ONCOLOGY, 2012, 102 (01) : 45 - 50
  • [50] Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE
    Liu, Qingxing
    Zang, Jie
    Sui, Huimin
    Ren, Jiakun
    Guo, Hua
    Wang, Hao
    Wang, Rongxi
    Jacobson, Orit
    Zhang, Jingjing
    Cheng, Yuejuan
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (03) : 386 - 392